Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  BULGARIAN STOCK EXCHANGE  >  Sopharma Trading AD    SO5   BG1100086070

SOPHARMA TRADING AD (SO5)
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials (BGN)
Sales 2018 896 M
EBIT 2018 14,3 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
Sales 2019 999 M
EBIT 2019 17,1 M
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0,27x
Capi. / Sales2019 0,24x
Capitalization 242 M
More Financials
Company
Sopharma Trading AD is a commercial company, which engages in the wholesale and distribution of pharmaceutical, non-drugs, and medical products.It offers logistic solutions for import, storage, and distribution of pharmaceutical products.Its products include medicines, medical devices, sanitary... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Latest news on SOPHARMA TRADING AD
07/06SOPHARMA TRADING : is the leader in Pharmaceutical sector in Capital Top 100 Ran..
PU
06/29SOPHARMA TRADING : Jsc. reports 8% growth in revenue and 6% higher profit before..
PU
06/22SOPHARMA TRADING : The No1 Bulgarian healthcare company Sopharma Trading expands..
PU
05/30SOPHARMA TRADING : Jsc. reports 13% growth in profit before taxes and 7% higher ..
PU
04/30SOPHARMA TRADING : Jsc. closes March 2018 with 35% growth in profit before taxes..
PU
01/31SOPHARMA TRADING : Jsc. closes 2017 with 10% growth in the accumulated revenue a..
PU
2017SOPHARMA TRADING : Jsc. reports in November 2017 41% growth оf profit befo..
PU
2017SOPHARMA TRADING : announces closing of the acquisition of PharmaStore chain of ..
PU
2017SOPHARMA TRADING : Jsc. reports 9% growth оf revenue in October, 2017
PU
2017SOPHARMA TRADING : becomes the marketer for Bulgaria of the product portfolio un..
PU
More news
Sector news : Generic Pharmaceuticals
07/20GLAXOSMITHKLINE : considers splitting up the group - FT
RE
07/20PFIZER : Biosimilar of Amgen's Neupogen Approved for Sale in the U.S.
DJ
07/20BAYER : to Stop Selling Essure in U.S.
DJ
07/20GLAXOSMITHKLINE : considers splitting up the group
RE
07/20GLAXOSMITHKLINE : Mulls Separation of Consumer Division -- FT
DJ
More sector news : Generic Pharmaceuticals
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 8,25  BGN
Spread / Average Target 12%
Managers
NameTitle
Dimitar Georgiev Dimitrov Chief Executive Officer & Executive Director
Ognian Ivanov Donev Chairman
Dimitar Bogomilov Chief Financial Officer
Denitsa Georgieva Director-Technology & Business Solutions
Angel Yordanov Yordanov Vice Chairman
Sector and Competitors